Future prospects for the chemotherapy of Chagas' disease - PubMed (original) (raw)
. 1999:59 Suppl 2:179-87.
Affiliations
- PMID: 10668262
Future prospects for the chemotherapy of Chagas' disease
A H Fairlamb. Medicina (B Aires). 1999.
Abstract
Over the last two decades, progress towards new drugs for the treatment of Chagas' disease has been disappointing. However, as a result of the parasite genome sequencing projects, the possibility of identifying novel drug targets through genomics, proteomics and bioinformatics has never been better. Progress towards the development of novel therapeutics, from target identification and validation by chemical and genetic means through to rational drug design, is illustrated with reference to the metabolism and functions of trypanothione, with particular emphasis on trypanothione reductase, one current drug target of choice.
Similar articles
- The chemotherapy of chagas' disease: an overview.
Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AO. Paulino M, et al. Mini Rev Med Chem. 2005 May;5(5):499-519. doi: 10.2174/1389557053765565. Mini Rev Med Chem. 2005. PMID: 15892691 Review. - Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K, Paulino M, Salas CO, Zarate-Ramos JJ, Vera B, Rivera G. Vázquez K, et al. Mini Rev Med Chem. 2017;17(11):939-946. doi: 10.2174/1389557517666170315145410. Mini Rev Med Chem. 2017. PMID: 28302040 Review. - Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution.
Rivarola HW, Paglini-Oliva PA. Rivarola HW, et al. Curr Drug Targets Cardiovasc Haematol Disord. 2002 Jun;2(1):43-52. doi: 10.2174/1568006023337745. Curr Drug Targets Cardiovasc Haematol Disord. 2002. PMID: 12769656 Review. - [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese. - Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease.
Neres J, Bryce RA, Douglas KT. Neres J, et al. Drug Discov Today. 2008 Feb;13(3-4):110-7. doi: 10.1016/j.drudis.2007.12.004. Drug Discov Today. 2008. PMID: 18275908 Review.
Cited by
- Understanding the Cross-Talk of Redox Metabolism and Fe-S Cluster Biogenesis in Leishmania Through Systems Biology Approach.
Kumar A, Chauhan N, Singh S. Kumar A, et al. Front Cell Infect Microbiol. 2019 Feb 4;9:15. doi: 10.3389/fcimb.2019.00015. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 30778378 Free PMC article. - Relevance of Trypanothione Reductase Inhibitors on Trypanosoma cruzi Infection: A Systematic Review, Meta-Analysis, and In Silico Integrated Approach.
Mendonça AAS, Coelho CM, Veloso MP, Caldas IS, Gonçalves RV, Teixeira AL, de Miranda AS, Novaes RD. Mendonça AAS, et al. Oxid Med Cell Longev. 2018 Oct 24;2018:8676578. doi: 10.1155/2018/8676578. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30473742 Free PMC article. - Natural Chagas disease in four baboons.
Williams JT, Dick EJ Jr, VandeBerg JL, Hubbard GB. Williams JT, et al. J Med Primatol. 2009 Apr;38(2):107-13. doi: 10.1111/j.1600-0684.2008.00308.x. Epub 2008 Jul 30. J Med Primatol. 2009. PMID: 18671766 Free PMC article. - 3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of Trypanosoma cruzi.
Menezes IR, Lopes JC, Montanari CA, Oliva G, Pavão F, Castilho MS, Vieira PC, Pupo MT. Menezes IR, et al. J Comput Aided Mol Des. 2003 May-Jun;17(5-6):277-90. doi: 10.1023/a:1026171723068. J Comput Aided Mol Des. 2003. PMID: 14635721 - Characterization of recombinant glutathionylspermidine synthetase/amidase from Crithidia fasciculata.
Oza SL, Ariyanayagam MR, Fairlamb AH. Oza SL, et al. Biochem J. 2002 Jun 15;364(Pt 3):679-86. doi: 10.1042/BJ20011370. Biochem J. 2002. PMID: 12049631 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical